We therefore undertook a post hoc analysis of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE; NCT02065791) trial [11] to evaluate the effects of canagliflozin on insulin use, including dose initiation, intensification, dose reduction and discontinuation, in people with CKD and type 2 diabetes. This evidence concerns the gene INS and diabetes mellitus.